Related Experiment Videos
Malignant mesothelioma of the pleural space
1Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Malignant pleural mesothelioma is an aggressive tumor associated with exposure to asbestos. Although this disease is rare, with an annual incidence in the United States of 2,000 to 3,000 cases, a steady rise in cases has been reported. Malignant pleural mesothelioma has a variable clinical presentation and may be difficult to diagnose. Pathologically, the disease is subdivided into three microscopic subtypes: epithelial, sarcomatous, and mixed histologies. Although there is no widely accepted staging system for mesothelioma, the Butchart, TNM, and Brigham staging systems have been used most commonly. Diffuse malignant pleural mesothelioma is resistant to standard modes of therapy and, if untreated, results in death 4 to 12 months from the time of diagnosis. For selected patients, an aggressive approach combining radical surgery with chemotherapy and radiotherapy has demonstrated a long-term survival advantage. New and innovative therapeutic modalities are presently being investigated in an attempt to provide viable alternatives for patients with early and advanced disease.
Insights
Malignant pleural mesothelioma, a rare asbestos-related cancer, presents challenges in diagnosis and treatment. Aggressive multimodal therapy offers survival benefits for select patients, with ongoing research for new treatments.
Area of Science:
- Oncology
- Pathology
- Environmental Medicine
Background:
- Malignant pleural mesothelioma is an aggressive cancer linked to asbestos exposure.
- The disease, though rare, shows a rising incidence in the United States.
- Clinical presentation is variable, making diagnosis difficult.
Purpose of the Study:
- To summarize the pathological subtypes, staging systems, and therapeutic approaches for malignant pleural mesothelioma.
- To highlight the challenges in diagnosis and treatment of this rare cancer.
- To discuss the potential of aggressive multimodal therapy and ongoing research.
Main Methods:
- Review of pathological classifications including epithelial, sarcomatous, and mixed histologies.
- Examination of commonly used staging systems: Butchart, TNM, and Brigham.
- Analysis of treatment outcomes for standard therapies and aggressive multimodal approaches.
Main Results:
- Malignant pleural mesothelioma exhibits resistance to standard therapies, with a poor prognosis if untreated.
- An aggressive approach combining surgery, chemotherapy, and radiotherapy shows long-term survival advantages for selected patients.
- New therapeutic modalities are under investigation for both early and advanced stages.
Conclusions:
- Malignant pleural mesothelioma requires specialized diagnostic and therapeutic strategies.
- Multimodal aggressive treatment can improve survival in eligible patients.
- Continued research into novel therapies is crucial for improving outcomes.